PCI Biotech Holding ASA (PCIB.OL)
NOK 1.32
(-0.75%)
NOK 1.32
(-0.75%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 319 Thousand NOK | -58.57% |
| 2022 | 770 Thousand NOK | -59.6% |
| 2021 | 1.9 Million NOK | 183.21% |
| 2020 | 673 Thousand NOK | -43.73% |
| 2019 | 1.19 Million NOK | 0.0% |
| 2018 | - NOK | 0.0% |
| 2017 | - NOK | 0.0% |
| 2016 | - NOK | 0.0% |
| 2015 | - NOK | 0.0% |
| 2014 | - NOK | 0.0% |
| 2013 | - NOK | 0.0% |
| 2012 | - NOK | -100.0% |
| 2011 | 1.8 Million NOK | -28.14% |
| 2010 | 2.51 Million NOK | 0.0% |
| 2009 | - NOK | 0.0% |
| 2008 | - NOK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - NOK | 0.0% |
| 2024 Q1 | - NOK | -100.0% |
| 2023 Q1 | 671 Thousand NOK | -12.86% |
| 2023 Q3 | - NOK | -100.0% |
| 2023 Q2 | 572 Thousand NOK | -14.75% |
| 2023 FY | 319 Thousand NOK | -58.57% |
| 2023 Q4 | 319 Thousand NOK | 0.0% |
| 2022 Q2 | 1.59 Million NOK | -8.98% |
| 2022 Q4 | 770 Thousand NOK | -46.3% |
| 2022 Q3 | 1.43 Million NOK | -9.87% |
| 2022 Q1 | 1.74 Million NOK | -8.29% |
| 2022 FY | 770 Thousand NOK | -59.6% |
| 2021 Q2 | 2.16 Million NOK | 329.31% |
| 2021 Q1 | 505 Thousand NOK | -24.96% |
| 2021 Q4 | 1.9 Million NOK | -5.13% |
| 2021 Q3 | 2 Million NOK | -7.33% |
| 2021 FY | 1.9 Million NOK | 183.21% |
| 2020 Q4 | 673 Thousand NOK | -10.51% |
| 2020 Q1 | 1.04 Million NOK | -12.37% |
| 2020 Q2 | 900 Thousand NOK | -14.12% |
| 2020 Q3 | 752 Thousand NOK | -16.44% |
| 2020 FY | 673 Thousand NOK | -43.73% |
| 2019 Q1 | 1.82 Million NOK | 0.0% |
| 2019 Q2 | 1.5 Million NOK | -17.47% |
| 2019 Q3 | 1.35 Million NOK | -10.42% |
| 2019 Q4 | 1.19 Million NOK | -11.41% |
| 2019 FY | 1.19 Million NOK | 0.0% |
| 2018 Q2 | - NOK | 0.0% |
| 2018 Q1 | - NOK | 0.0% |
| 2018 Q4 | - NOK | 0.0% |
| 2018 FY | - NOK | 0.0% |
| 2018 Q3 | - NOK | 0.0% |
| 2017 Q3 | - NOK | 0.0% |
| 2017 Q2 | - NOK | 0.0% |
| 2017 Q1 | - NOK | 0.0% |
| 2017 FY | - NOK | 0.0% |
| 2017 Q4 | - NOK | 0.0% |
| 2016 Q2 | - NOK | 0.0% |
| 2016 Q1 | - NOK | 0.0% |
| 2016 Q3 | - NOK | 0.0% |
| 2016 Q4 | - NOK | 0.0% |
| 2016 FY | - NOK | 0.0% |
| 2015 Q1 | - NOK | 0.0% |
| 2015 FY | - NOK | 0.0% |
| 2015 Q3 | - NOK | 0.0% |
| 2015 Q2 | - NOK | 0.0% |
| 2015 Q4 | - NOK | 0.0% |
| 2014 FY | - NOK | 0.0% |
| 2014 Q4 | - NOK | 0.0% |
| 2014 Q2 | - NOK | 0.0% |
| 2014 Q3 | - NOK | 0.0% |
| 2014 Q1 | - NOK | 0.0% |
| 2013 Q2 | - NOK | 0.0% |
| 2013 Q3 | - NOK | 0.0% |
| 2013 Q4 | - NOK | 0.0% |
| 2013 FY | - NOK | 0.0% |
| 2013 Q1 | - NOK | 0.0% |
| 2012 Q1 | - NOK | -100.0% |
| 2012 Q2 | - NOK | 0.0% |
| 2012 FY | - NOK | -100.0% |
| 2012 Q3 | 4.94 Million NOK | 0.0% |
| 2012 Q4 | - NOK | -100.0% |
| 2011 FY | 1.8 Million NOK | -28.14% |
| 2011 Q1 | - NOK | -100.0% |
| 2011 Q3 | - NOK | 0.0% |
| 2011 Q2 | - NOK | 0.0% |
| 2011 Q4 | 1.8 Million NOK | 0.0% |
| 2010 Q3 | 6.1 Million NOK | -27.83% |
| 2010 Q2 | 8.45 Million NOK | 0.0% |
| 2010 FY | 2.51 Million NOK | 0.0% |
| 2010 Q4 | 2.51 Million NOK | -58.82% |
| 2009 FY | - NOK | 0.0% |
| 2009 Q4 | 139 Thousand NOK | 0.0% |
| 2008 FY | - NOK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Arctic Bioscience AS | 2.04 Million NOK | 84.429% |
| Aqua Bio Technology ASA | 7.12 Million NOK | 95.522% |
| ArcticZymes Technologies ASA | 12.58 Million NOK | 97.466% |
| BerGenBio ASA | 418 Thousand NOK | 23.684% |
| Hofseth BioCare ASA | 136.78 Million NOK | 99.767% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | 3.71 Million NOK | 91.409% |